EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study

Kezhi Zhou, Junyi Zhou, Leting Zhou, Jing Xue, Bin Liu, Zhijian Zhang, Xiran Zhang, Ting Cai, Sijia Shao, Biao Huang iD, Yi Zhang, Zhigang Hu und 2 weitere

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0302100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Kezhi Zhou und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing M…. Hauptthemen laut MEDLINE: Glomerulonephritis, Membranous, Receptors, Phospholipase A2, Rituximab, Remission Induction. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wuxi Medical Innovation Team Project, the Top Talent Support Program for young and middle-aged people of Wuxi Health Committee, Cohort and Clinical Research Program of Wuxi Medical Center, Nanjing Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

M-type phospholipase A2 receptor (PLA2R) is a major auto-antigen of primary membranous nephropathy(PMN). Anti-PLA2R antibody levels are closely associated with disease severity and therapeutic effectiveness. Analysis of PLA2R antigen epitope reactivity may have a greater predictive value for remission compared with total PLA2R-antibody level. This study aims to elucidate the relationship between domain-specific antibody levels and clinical outcomes of PMN.

Methods

This retrospective analysis included 87 patients with PLA2R-associated PMN. Among them, 40 and 47 were treated with rituximab (RTX) and cyclophosphamide (CTX) regimen, respectively. The quantitative detection of -immunoglobulin G (IgG)/-IgG4 targeting PLA2R and its epitope levels in the serum of patients with PMN were obtained through time-resolved fluorescence immunoassays and served as biomarkers in evaluating the treatment effectiveness. A predictive PMN remission possibility nomogram was developed using multivariate logistic regression analysis. Discrimination in the prediction model was assessed using the area under the receiver operating characteristic curve (AUC-ROC).Bootstrap ROC was used to evaluate the performance of the prediction model.

Results

After a 6-month treatment period, the remission rates of proteinuria, including complete remission and partial remission in the RTX and CTX groups, were 70% and 70.21% (P = 0.983), respectively. However, there was a significant difference in immunological remission in the PLA2R-IgG4 between the RTX and CTX groups (21.43% vs. 61.90%, P = 0.019). Furthermore, we found differences in PLA2R-CysR-IgG4(P = 0.030), PLA2R-CTLD1-IgG4(P = 0.005), PLA2R-CTLD678-IgG4(P = 0.003), and epitope spreading (P = 0.023) between responders and non-responders in the CTX group. Multivariate logistic analysis showed that higher levels of urinary protein (odds ratio [OR], 0.49; 95% confidence interval [CI], 0.26–0.95; P = 0.035) and higher levels of PLA2R-CTLD1-IgG4 (OR, 0.79; 95%CI,0.62–0.99; P = 0.041) were independent risk factors for early remission. A multivariate model for estimating the possibility of early remission in patients with PMN is presented as a nomogram. The AUC-ROC of our model was 0.721 (95%CI, 0.601–0.840), in consistency with the results obtained with internal validation, for which the AUC-ROC was 0.711 (95%CI, 0.587–0.824), thus, demonstrating robustness.

Conclusions

Cyclophosphamide can induce immunological remission earlier than rituximab at the span of 6 months. The PLA2R-CTLD1-IgG4 has a better predict value than total PLA2R-IgG for remission of proteinuria at the 6 th month.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerulonephritis, MembranousReceptors, Phospholipase A2RituximabRemission InductionAutoantibodiesHumansMaleFemaleRetrospective StudiesMiddle AgedAdultImmunoglobulin GCyclophosphamideAgedROC CurveTreatment Outcome

Substanzen

Receptors, Phospholipase A2RituximabAutoantibodiesPLA2R1 protein, humanImmunoglobulin GCyclophosphamide

Autor:innen und Institutionen

  • Department of Nephrology, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, P.R. China.
  • College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou, P.R. China.
  • NHC Key Laboratory of Nuclear Medicine, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, P.R. China.
  • Medical Laboratory, The Affiliated Wuxi Children's Hospital of Nanjing Medical University, Wuxi, P.R. China.

ORCID-Profile: Biao Huang, Liang Wang

Förderung

  • Wuxi Medical Innovation Team Project
  • the Top Talent Support Program for young and middle-aged people of Wuxi Health Committee
  • Cohort and Clinical Research Program of Wuxi Medical Center, Nanjing Medical University
  • Natural Science Foundation of Jiangsu Province
  • National Natural Science Foundation of China
  • Natural Science Foundation of Zhejiang Province
  • Scientific research project of Zhejiang Provincial Education Department
  • Scientific Research Projects of Wuxi Municipal Health Commissio

Zitieren

APA

Zhou, K., Zhou, J., Zhou, L., Xue, J., Liu, B., Zhang, Z., Zhang, X., Cai, T., Shao, S., Huang, B., Zhang, Y., Hu, Z., Wang, L., & Liu, X. (2024). Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study. PLOS ONE. https://doi.org/10.1371/journal.pone.0302100

Vancouver

Zhou K, Zhou J, Zhou L, Xue J, Liu B, Zhang Z, et al. Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study. PLOS ONE. 2024. doi:10.1371/journal.pone.0302100

BibTeX
@article{Zhou2024,
  author = {Zhou, Kezhi and Zhou, Junyi and Zhou, Leting and Xue, Jing and Liu, Bin and Zhang, Zhijian and Zhang, Xiran and Cai, Ting and Shao, Sijia and Huang, Biao and Zhang, Yi and Hu, Zhigang and Wang, Liang and Liu, Xiaobin},
  title = {Predictive value of the domain specific PLA2R antibodies for clinical remission in patients with primary membranous nephropathy: A retrospective study},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0302100}
}
Kostenlos starten →